Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →🚫 This provider appears on the OIG List of Excluded Individuals/Entities (LEIE)
Exclusion type: 1128a1 · Date: 20150618 · State: TX
Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
1,475
Total Claims
$8.3M
Drug Cost
281
Beneficiaries
$29K
Cost/Patient
Risk Score Breakdown 31/100
Score components are additive. Read full methodology
Peer Comparison vs. 8,541 Hematology-Oncology providers
+28%
Opioid rate vs peers
8.0% vs 6.3% avg
+116%
Cost per patient vs peers
$29K vs $14K avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
Opioid Prescribing
8.0%
Opioid Rate
118
Opioid Claims
$3,220
Opioid Cost
29.7%
Long-Acting Rate
Brand vs Generic
Brand: 0 claims · $0
Generic: 871 claims · $300K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Ibrutinib | 54 | $851K |
| Lenvatinib Mesylate | 26 | $619K |
| Enzalutamide | 44 | $598K |
| Pomalidomide | 25 | $598K |
| Eltrombopag Olamine | 37 | $493K |
| Palbociclib | 29 | $471K |
| Ribociclib Succinate | 20 | $362K |
| Apalutamide | 20 | $312K |
| Nilotinib Hcl | 29 | $307K |
| Ruxolitinib Phosphate | 15 | $266K |
| Alpelisib | 20 | $251K |
| Olaparib | 22 | $237K |
| Axitinib | 13 | $212K |
| Osimertinib Mesylate | 12 | $211K |
| Bosutinib | 19 | $206K |
Prescribing Profile
Patient Profile
74
Avg Age
66%
Female
2.18
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About